Skip to main content
NewslettersWatchlist

Regeneron Pharmaceuticals(REGN-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low891.67
Day High908.81
Open:901.26
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Barchart
Technology Stocks Power the Broader Market Higher
Barchart
Stock Indexes Rise in Afternoon Trade
Barchart
Stocks Slightly Higher as US Mar PPI Climbs Less Than Expected
Motley Fool
Should You Sell This Stock Following a Regulatory Roadblock?
Motley Fool
Stock-Split Watch: Are These 2 Top Growth Stocks Next?
Barchart
Stocks End Lower as Hawkish Fed Comments Push Bond Yields Higher
Barchart
Stocks Slip on Corporate News and Hawkish Fed Comments
Barchart
Negative Corporate News Undercuts Stocks
Motley Fool
Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon.
Motley Fool
2 Biotech Stocks to Buy Hand Over Fist in March
Barchart
Stocks Close Higher as Inflation Concerns Ease
Barchart
Stocks Gain on Relief That Price Pressures are Abating
Motley Fool
2 No-Brainer Biotech Stocks to Buy Right Now
Motley Fool
2 Top Growth Stocks to Buy With $1,000 Right Now
Motley Fool
These 2 Stocks Are Trying to Ride the Ozempic Bandwagon: Are They Buys?
Motley Fool
Stock-Split Watch: Could These 2 Market-Beaters Be Next?
Barchart
Markets Today: Stocks Higher on Strong Tech Earnings Despite Hot Payroll Report
AllPennyStocks.com
Biotech Shares Soar Premarket On Sale Of R&D Assets
Motley Fool
3 Magnificent Stocks to Buy and Hold Forever
Motley Fool
2 Smart Growth Stocks to Buy Hand Over Fist in 2024
Barchart
S&P 500 Index Posts 2-year High on Friendly U.S. PPI Report
Motley Fool
Could Regeneron Stock Help You Retire a Millionaire?
Newswire.ca
Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries
Motley Fool
2 Healthcare Stocks That Turned $1,000 Into $2,400 (or More)
Motley Fool
Where Will Regeneron Pharmaceuticals Be in 1 Year?
Motley Fool
It's Almost 2024: 3 Top Stocks to Buy Before the New Year
Motley Fool
3 Stocks to Buy Before 2024 That Can Set You Up For Life
Motley Fool
Could Regeneron Pharmaceuticals Stock Help You Become a Millionaire?
Motley Fool
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
Motley Fool
2 Soaring Stocks to Buy and Hold
Motley Fool
1 Supercharged Growth Stock That Could Make You a Millionaire in 10 Years
Motley Fool
Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient

Profile

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also developed an antibody cocktail for COVID-19, REGEN-COV. REGEN-COV is a cocktail of two monoclonal antibodies and was designed specifically to block the infectivity of SARS-CoV-2, the virus that causes COVID-19. Regeneron has a collaboration agreement with Roche for the same. While Regeneron has co-developed Eylea with Bayer's HealthCare unit, Praluent was co-developed with Sanofi. Regeneron collaborated with Bayer for the joint development and commercialization of co-formulated combinations of Eylea, rinucumab and nesvacumab for the treatment of ocular diseases or disorders outside the United States.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.